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Small-moleculeCCR5 inhibitors such as vicriviroc (VVC) andmaraviroc (MVC) are allostericmodulators that impairHIV-1 entry by
stabilizing aCCR5 conformation that the virus recognizes inefficiently. Viruses resistant to these compounds are able to bind the in-
hibitor-CCR5 complexwhile also interactingwith the free coreceptor. CCR5 also interacts intracellularlywithGproteins, as part of its
signal transduction functions, and this process alters its conformation.Herewe investigatedwhether the action ofVVCagainst inhibi-
tor-sensitive and -resistant viruses is affected bywhether or notCCR5 is coupled toGproteins such asGi. TreatingCD4
T cells with
pertussis toxin to uncouple theGi subunit fromCCR5 increased the potency ofVVCagainst the sensitive viruses and revealed that
VVC-resistant viruses use the inhibitor-bound formofGi-coupledCCR5more efficiently than they use uncoupledCCR5. Supportive
evidencewas obtained by expressing a signaling-deficientCCR5mutantwith an impaired ability to bind toGproteins, aswell as two
constitutively activemutants that activateGproteins in the absence of external stimuli. The implication of these various studies is that
the association of intracellular domains of CCR5with the signalingmachinery affects the conformation of the external and transmem-
brane domains andhow they interactwith small-molecule inhibitors ofHIV-1 entry.
The sequential binding of the trimeric envelope glycoprotein(Env) complex to the CD4 receptor and the CCR5 coreceptor
mediates the entry of human immunodeficiency virus type 1
(HIV-1) into host cells (1–3). The interaction between the Env
gp120 subunit and CCR5 involves two structural elements: a
gp120 site comprising the CD4-induced, 4-stranded bridging
sheet region and the base of V3 recognizes the CCR5 N terminus
(NT), while residues near the V3 tip interact with the second ex-
tracellular loop (ECL2) (4, 5). Small-molecule CCR5 inhibitors
such as the licensed drug maraviroc (MVC) and the experimental
compound vicriviroc (VVC) impair this interaction by a predom-
inantly noncompetitive mechanism. They do so by binding in a
hydrophobic cavity located within the transmembrane (TM) he-
lices, thereby stabilizing a CCR5 conformation that HIV-1 recog-
nizes inefficiently (6, 7). Viruses resistant to small-molecule CCR5
inhibitors can be generated in vitro and in vivo; the dominant
route to resistance involves the acquisition of sequence changes,
particularly in V3, that render gp120 capable of recognizing the
inhibitor-CCR5 complex while retaining the ability to also inter-
act with the free coreceptor (8–10).
The chemokine receptorCCR5 is amember of the seven-trans-
membrane G-protein-coupled receptor (GPCR) superfamily.
GPCRs can acquire multiple conformations as they transit from
the agonist-bound, signaling-active conformation to the more
stable antagonist-bound, signaling-inactive conformation (11,
12).When CCR5 is activated by chemokine ligands, its intracellu-
lar domains can associate with four classes of heterotrimeric G
proteins: Gi, Gs, Gq, and G12/13 (13). Among these intracel-
lular components of the signal transduction machinery, Gi is
uniquely sensitive to ADP ribosylation by pertussis toxin (PTX)
(14, 15). Questions have arisen as to whether gp120 binding to
CCR5 induces signals similar to those triggered by chemokines
and whether such signals play any role in the entry or postentry
stages of the HIV-1 replication cycle. There have been no defini-
tive answers, not least because various studies have used multiple
different cell types that differ in their activation state and therefore
yield inconsistent or contradictory outcomes (reviewed by Wu
and Yoder [16]). Early studies in which Gi-mediated CCR5 sig-
naling was inhibitedwith PTX or that usedCCR5mutants with an
impaired ability to couple toGproteins (e.g., CCR5-R126N) dem-
onstrated that signaling via CCR5 is dispensable for HIV-1 repli-
cation in cell lines or activated T cells (17–19). More recently, Env
was found to trigger actin rearrangement through Gi-mediated
CXCR4 signaling or Gq-mediated CCR5 signaling. These events
were shown to be critical at both entry and postentry stages of
HIV-1 replication, particularly in resting T cells (20–23).We have
obtained evidence that CCR5 exists in multiple cell surface con-
formations that differ in their antigenicity, i.e., their reactivity
with specific monoclonal antibodies (MAbs) (24). Some of these
antigenic forms represent distinct CCR5 subsets with different
functional properties and membrane localizations (24). We hy-
pothesized that these CCR5 subsets might differ in the ability to
bind various ligands, including the HIV-1 Env complex and
small-molecule inhibitors (24, 25). One source of conformational
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diversity is whether CCR5 is or is not associated with G proteins
and other signaling components (25).
In this study, we investigated the effects of uncoupling CCR5
fromG proteins on the actions of VVC against VVC-sensitive and
-resistant viruses in primary CD4 T cells and the U87-CD4 cell
line. To do so, we used PTX to uncouple CCR5 from Gi in the
primary T cells and expressed a signaling-deficient mutant
(SDM), CCR5-R126N, in the cell line. Conversely, we also tested
two constitutively active mutants (CAM), CCR5-T82P and
CCR5-T82K, which activate G proteins in the absence of any ex-
ternal stimulus (26). Overall, we conclude that VVC-resistant vi-
ruses use the inhibitor-bound form of Gi-coupled CCR5 more
efficiently than the uncoupled CCR5 configuration. In addition,
uncoupling CCR5 fromGi increases the potency of VVC against
sensitive viruses. The implication is that CCR5 association with
the signaling machinery induces conformational changes that af-
fect how small-molecule CCR5 inhibitors act againstHIV-1 entry.
MATERIALS AND METHODS
Cells and plasmids. U87-CD4 cells, contributed by HongKui Deng and
Dan Littman, were obtained from the NIH AIDS Research and Reference
Reagent Program (ARRRP), and 293T cells were obtained from theAmer-
ican Type Culture Collection (ATCC). Cell lines were maintained in Dul-
becco’s modified Eagle medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 100 U/ml penicillin, 100 g/ml streptomycin, and 2
mM L-glutamine.
Peripheral blood mononuclear cells (PBMC) were purified and stim-
ulated as previously described (8). CD4 T cells were purified from
PBMC by use of a Dynal CD4 positive selection kit (Invitrogen, Carlsbad,
CA) after 3 days of stimulation. CD4 T cells were treated with PTX or B
oligomer (Sigma-Aldrich) on the same day they were isolated.
The CCR5-WT plasmid was generated by cloning human CCR5
cDNA tagged with the C-terminal 1D4 epitope (TETSQVAPA) into
pcDNA3.1 () as described previously (27). CCR5 mutants were gener-
ated by site-directedmutagenesis of CCR5-WT. The primers used to gen-
erate CCR5-R126N were 5=-CTCCTGACAATCGATAACTACCTGGCT
GTCGTCC-3= (forward) and 5=-GGACGACAGCCAGGTAGTTATCGA
TTGTCAGGAG-3= (reverse), those for CCR5-T82P were 5=-GACCTGT
TTTTCCTTCTTCCTGTCCCCTTCTGGGCTC-3= (forward) and 5=-GA
GCCCAGAAGGGGACAGGAAGAAGGAAAAACAGGTC-3= (reverse),
and those for CCR5-T82K were 5=-GACCTGTTTTTCCTTCTTAAAGT
CCCCTTCTGGGCTCAC-3= (forward) and 5=-GTGAGCCCAGAAGGG
GACTTTAAAAAGGAAAAACAGGTC-3= (reverse). The pNLluc-AM
and PCI-env plasmids used for Env-pseudovirus production have been
described previously (28). The pNL4-3/env chimeric clonal proviral plas-
mids used for the production of infectious molecular clones were con-
structed as described elsewhere (8, 29). The Par-4V3, Par-3FP, Res-4V3,
and Res-3FP env genes in PCI-env and pNL4-3/env correspond to clones
CC1/85 cl.7, CC1/85 cl.6, CC101.19 cl.7, and D1/85.16 cl.23, respectively
(8, 30). The Par-4V3 (CC1/85 cl.7; GenBank accessionno. AY357341) and
Par-3FP (CC1/85 cl.6; GenBank accession no. AY357338) env genes were
directly cloned from the VVC-sensitive patient isolate CC1/85. When
CC1/85 was propagated in vitro in the presence of the CCR5 inhibitors
AD101 and VVC, two inhibitor-resistant isolates were selected: CC101.19
and D1/85.16, respectively. The Res-4V3 (CC101.19 cl.7; GenBank acces-
sion no. AY357465) and Res-3FP (D1/85.16 cl.23; GenBank accession no.
FJ713453) env genes were cloned from the CC101.19 and D1/85.16 iso-
lates, respectively (8, 30). Compared to other sensitive env genes from the
CC1/85 isolate, the Par-4V3 and Par-3FP env genes shared the most se-
quence similarity to the Res-4V3 andRes-3FP env genes, respectively; they
were therefore chosen as the comparator parental viruses (28).
CCR5 transfection and Env-pseudovirus infection. U87-CD4 cells
were transfected with CCR5-expressing plasmids by use of Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions. One day
later, the cells were washed twice with culture medium and then seeded
into 96-well plates at a density of 1 104 cells per well in 50l of medium
for one more day. They were then infected in the presence or absence of
VVC (50 l) with Env-pseudoviruses, as previously described (28).
Briefly, Env-pseudoviruses were incubated with magnetic beads (Viro-
Mag R/L; Boca Scientific, Boca Raton, FL) for 15 min, added to the trans-
fected cells, and placed on a Super Magnetic plate (Boca Scientific) for 10
min. The luciferase signal was measured at 72 h postinfection, using
Bright-Glo luciferase substrate (Promega Inc., Madison, WI). There was
nomeasurable luminescence from uninfected cells (i.e., background con-
trol). Inhibition of HIV-1 entry in the presence of VVC was calculated as
100 [1 (LucVVC/Luccontrol)], with the control being infectionwithout
any inhibitor.
Infection inhibition assay. Infectious clonal virus stocks were pre-
pared by transient transfection of 293T cells with pNL4-3/env plasmids by
use of Lipofectamine 2000 (Invitrogen), as described previously (8). All
stocks of infectious viruses were passed through a 0.45-m filter and
stored in aliquots at 80°C. The 50% tissue culture infective doses
(TCID50) for PBMC were determined by standard methods (31).
PTX (or B oligomer)-treated or control CD4 T cells were seeded at
1 105 cells per well in a 96-well plate. The CD4 T cells, obtained from
a single donor, consisted of equal numbers from each of the two stimula-
tion conditions outlined above. VVCwas diluted in culturemedium (with
or without 10 MH89, as indicated) to twice the final concentration and
added (50l) to the cells (50l) for 1 h at 37°C. Infection was initiated by
adding 1,000 TCID50 of a clone (100 l) for 6 h, and then the cells were
washed twice and resuspended in culture medium containing the appro-
priate finalVVCconcentration.Unlike in the pseudovirus infection assays
described above, magnetic beads were not used with replication-compe-
tent viruses. The production of HIV-1 p24 antigen after 7 days was quan-
tified by enzyme-linked immunosorbent assay (ELISA) (32). Inhibition of
HIV-1 replication in the presence of VVC was calculated as 100  [1 
(p24VVC/p24control)], with the control being infection without any inhib-
itor.
125I-RANTES binding assay. CCR5-transfected or control U87-CD4
cells were scraped from the surface of the culture flask, washed once with
phosphate-buffered saline (PBS), and resuspended in the same buffer.
The cells (800,000) were then plated in a 96-well plate and resuspended in
100 l of binding buffer (50 mM HEPES, pH 7.4, 1 mM CaCl2, 5 mM
MgCl2, 0.5% bovine serum albumin [BSA]) in the presence of increasing
VVC concentrations. After incubation with VVC for 1 h at room temper-
ature, 400 pM 125I-RANTES (PerkinElmer) was added for 1 h. The plates
were then centrifuged and the cells washed twice with 200 l of PBS.
After the last wash, the cells were transferred to scintillation vials for
measurement of bound 125I-RANTES, using a Packard model 5530
gamma counter (Packard Instruments, Meriden, CT). Inhibition of
125I-RANTES in the presence of VVC was calculated as 100  [1 
(BindingVVC/Bindingcontrol)], with the control being infection without
any inhibitor.
PKA assay. CD4 T cells (106 cells) were incubated with the protein
kinase A (PKA) inhibitor H89 (Sigma-Aldrich) for 1 h, washed with PBS,
and then incubated for 10 min with 500 l of lysis buffer (20 mM mor-
pholinepropanesulfonic acid [MOPS], 50 mM -glycerol phosphate, 50
mMsodiumfluoride, 1mMsodiumvanadate, 5mMEGTA, 2mMEDTA,
1%NP-40, 1mMdithiothreitol [DTT], 1mMbenzamidine, 1 mM phenyl-
methylsulfonyl fluoride [PMSF], and 10 g/ml leupeptin and aprotinin).
Cell lysates were then spun down, and the total protein content was quan-
tified using a Pierce bicinchoninic acid (BCA) protein assay kit (Thermo
Scientific, Rockford, IL). PKA activity in 100 ng of the lysatewasmeasured
using a PKA assay kit according to the manufacturer’s instructions (Enzo
Lifesciences, Farmingdale, NY).
Western blotting.U87-CD4 cells transfected with CCR5-WT, CCR5-
T82P, or CCR5-T82K for 48 h were incubated with or without RANTES
for 5min orwith TAK779 for 15min. Cells were lysed in buffer containing
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 2 mM EDTA, and 1% Triton
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X-100. The total protein content was quantified using a BCA assay kit
(Thermo Scientific, Rockford, IL). The cellular proteins (10 g in total)
were separated in an 8% Tris-glycine gel (Invitrogen) for 2 h, transferred
to a polyvinylidene difluoride (PVDF) membrane overnight, and probed
with antibodies that recognize either phosphorylated extracellular signal-
regulated kinase 1/2 (P-ERK1/2) (clone D13.14.4E) or ERK1/2 (clone
3A7) (Cell Signaling Technology, Danvers, MA), as previously described
(33). The signal intensities were quantified using ImageJ (National Insti-
tutes of Health, Bethesda, MD).
Data analysis.All titration curveswere generatedusingPrism (Graph-
pad Software, San Diego, CA) and used to derive the maximum percent
inhibition (MPI) and 50% effective concentrations (EC50s). P values were
calculated using the one-tailed Mann-Whitney U test, and P values of
0.05 were considered statistically significant.
RESULTS
Uncoupling CCR5 from the Gi subunit affects HIV-1 sensitiv-
ity to VVC.We treated primary human CD4 T cells with PTX to
uncouple the Gi subunit from CCR5 and then infected the cells
with genetically related, fully infectious, clonal, VVC-sensitive or
-resistant viruses in the presence of increasing VVC concentra-
tions. PTX treatment increased the potency of VVC against the
two parental, VVC-sensitive viruses, Par-4V3 and Par-3FP, albeit
only modestly; the EC50s were reduced by 4-fold (P  0.019)
and2-fold (P 0.028), respectively (Fig. 1A; Table 1). A more
substantial effect of VVCwas seen with the VVC-resistant viruses,
Res-4V3 andRes-3FP.Onemeasure of resistance is theMPI value,
which reflects how efficiently a resistant virus uses the VVC-CCR5
complex for entry (34): the higher the MPI, the less efficiently the
complex is used than the inhibitor-free form, and the lower the
extent of residual VVC-insensitive replication (34–36). At high
VVC concentrations, theMPI values for the Res-4V3 andRes-3FP
VVC-resistant viruses increased from 43% and 46%, respectively,
in control cells to 78% and 79%, respectively, in PTX-treated cells
(P 0.016 and P 0.048, respectively) (Fig. 1A; Table 1). Similar
inhibition trends were obtained with Par-4V3 and Res-4V3 when
FIG 1 Effect of PTX treatment on inhibition of HIV-1 replication by VVC. CD4 T cells were treated overnight with PTX (100 ng/ml), or not, incubated for 1
h with a range of VVC concentrations, and then infected with the indicated viruses. The cells were washed 6 h later and then supplemented with medium
containing the same VVC concentrations. The data represent the percent inhibition of HIV-1 replication (measured at 7 days postinfection by p24 ELISA)
relative to that in the absence of VVC (0%). The average values (	 standard errors of the means [SEM]) for at least five independent experiments, using CD4
T cells from a different donor in each experiment, are shown. The numbers in gray indicate the MPI values.
TABLE 1 VVC inhibition of HIV-1 replication in PTX-treated or
control CD4 T cellsa
Virus and treatment
Avg	 SEM
MPI EC50
Par-4V3 104	 1.7 53	 25
Par-4V3 PTX 101	 3.7 12	 7.4
Res-4V3 43	 7.0 0.81	 0.49
Res-4V3 PTX 78	 9.0 1.5	 0.86
Par-3FP 107	 1.6 33	 5.0
Par-3FP PTX 105	 2.7 16	 5.8
Res-3FP 46	 11 4.0	 2.3
Res-3FP PTX 79	 10 0.56	 0.20
a EC50 and MPI values were derived from fitted curves generated for each independent
donor. Average EC50 and MPI values (	 SEM) for all donors were calculated and are
shown in this table. The MPI values are fitted plateau values. For the VVC-resistant
viruses, the EC50 values are the VVC concentrations that inhibit replication to an extent
corresponding to half the plateau values (i.e.,
50% inhibition). As such, these EC50
values do not reflect the potency of VVC against infection in the same way as for VVC-
sensitive viruses, which limits how the data can be interpreted. The same data set is
displayed in Fig. 1.
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MVC was used instead of VVC (data not shown). The effect of
PTXonVVC inhibition of virus entrywas also assessed in a single-
cycle assay using Tzm-bl cells. In the presence of PTX, there was a
7-fold decrease in the EC50 for VVC against Par-4V3 and an in-
crease in the MPI against Res-4V3 (from 51% to 87%) compared
to those for control cells (data not shown). These effects of PTX
are consistent with the ones we observed using CD4 T cells,
suggesting that PTX treatment does modify how VVC affects
HIV-1 entry, irrespective of any additional effects it may have on
postentry events. Note that PTX treatment caused no overall
change in the level of CCR5 expression on theCD4T cell surface,
as judged by staining with MAb PA14 or 2D7 (data not shown).
Treating the CD4 T cells with PTX reduced the replication of
all four of the test viruses by 2- to 3-fold (data not shown). When
the virus inoculum added to the PTX-treated CD4 T cells was
increased to compensate for this reduction in replication com-
pared to that in control cells, the VVC inhibition profiles for the
inhibitor-sensitive and -resistant viruses Par-4V3 and Res-4V3
were similar to those obtained previously (data not shown). This
result suggests that the above changes in EC50 andMPI valueswere
not due to PTX affecting the susceptibility of the target cells to
virus infection. We also used the data set in Table 1 to perform a
correlation analysis between the susceptibilities of the cells to infec-
tion by the various viruses, based on the extent of virus replication,
and the EC50 orMPI values (as appropriate). These correlationswere
weak and did not reach statistical significance (P 0.05).
Overall, the above-described experiments showed that PTX
treatment increased the potency of VVC against the sensitive vi-
ruses (reduced EC50) while decreasing the ability of the resistant
viruses to use the VVC-CCR5 complex (increased MPI). Our in-
terpretation is that VVC-resistant viruses use the VVC-CCR5
complex less efficiently when CCR5 is uncoupled from Gi.
The effect of PTXonHIV-1 sensitivity toVVC ismediatedby
its catalytic subunit. PTX consists of two subunits: an enzymati-
cally active A protomer that ribosylates the Gi subunit and pre-
vents it from coupling to the cognate GPCR and a binding (B)
oligomer that mediates the toxin’s biological effects indepen-
dently ofGi (Fig. 2A) (37, 38). To determinewhether the effect of
PTX on VVC activity is mediated by Gi uncoupling, we per-
formed an experiment similar to that described for Fig. 1A, but
now using the noncatalytic B oligomer. Unlike PTX, treating the
cells with the B oligomer had no effect on the VVC inhibition
profile for either Par-4V3 or Res-4V3 (Fig. 2B and C). Similar
results were obtained using the second pair of VVC-sensitive (Par-
3FP) and -resistant (Res-3FP) viruses (data not shown).
G-protein coupling to GPCRs (in this case, CCR5) involves a
heterotrimeric complex containing the , , and  subunits. The
activation of CCR5 signaling through Gi leads to dissociation of
the heterotrimer into a GTP-bound, activated Gi subunit and a
G dimer. The activated Gi subunit inhibits adenylyl cyclase
(AC) activity, resulting in a decrease in the intracellular cyclic
AMP (cAMP) concentration and a concomitant reduction in PKA
FIG 2 Effect of the B oligomer, the noncatalytic subunit of PTX, on inhibition of HIV-1 replication by VVC. (A) Schematic representation of the mechanism of
action of PTX. The PTX catalytic subunit, the A protomer, ribosylates the Gi subunit and uncouples it from the GPCR (i.e., CCR5). As a result of Gi
uncoupling, cAMP levels increase, driving the activation of PKA and other cAMP-dependentmolecules (37). (B andC)CD4T cells were treated overnight with
100 ng/ml of B oligomer or PTX or left untreated and then were incubated for 1 h with a range of VVC concentrations prior to infection with the VVC-sensitive
virus Par-4V3 (B) or theVVC-resistant virus Res-4V3 (C), as indicated. The cells werewashed 6 h later and then supplementedwithmedium containing the same
VVC concentrations. The data represent the percent inhibition of HIV-1 replication (measured at 7 days postinfection by p24 ELISA) relative to that in the
absence of VVC (0%). The average values (	 SEM) for three independent experiments, using CD4T cells from a different donor in each experiment, are shown
in panels B and C.
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activity. When PTX ribosylates the Gi subunit, it remains locked
in the GDP-bound, inactive state that is unable to inhibit AC. As a
result, cAMP concentrations rise and PKA becomes more active
(Fig. 2A).
To determine whether PTXmediates its effect on VVC inhibi-
tion through cAMP-dependent PKA activation, we used the PKA
inhibitor H89 (39). We first titrated H89 on CD4 T cells to de-
termine the optimal concentration that significantly inhibits PKA
activity without compromising virus entry (Fig. 3A). At an H89
concentration of 10 M, PKA was significantly inhibited (by
80%), but the replication of Res-4V3 and the other test viruses was
only modestly reduced (by35%) (Fig. 3A and data not shown).
We next evaluated whether H89 altered the VVC inhibition pat-
terns in the presence and absence of PTX. When PTX was absent,
the same 10 M H89 concentration did not affect the VVC inhi-
bition profile for Par-4V3 or Res-4V3 in CD4 T cells compared
to the control (Fig. 3B and C). Moreover, H89 did not reverse the
effect of PTX on the VVC inhibition profile for either Par-4V3 or
Res-4V3 (Fig. 3B and C). Cumulatively, these results indicate that
PTXmost likely affects howVVC inhibits HIV-1 entry by amech-
anism that is independent of downstream signaling events such as
PKA activation. We propose that the effects of PTX are, instead, a
direct result of conformational changes induced in CCR5 by the
uncoupling of Gi, an event driven by the PTX catalytic subunit.
Use of VVC-bound, signaling-deficient, or constitutively ac-
tive CCR5 mutants.We next assessed whether the effects of PTX
could bemimicked or expandeduponby the use ofCCR5mutants
with different basal or chemokine-induced signaling capacities.
An R126N change in the DRY motif of CCR5 and other GPCRs
disables G-protein coupling and agonist-induced signal transduc-
tion (40). Conversely, several substitutions at residue Thr-82 (e.g.,
T82P and T82K) in the CCR5 TM2 domain cause conformational
changes thatmake the receptor constitutively active, in that it now
signals in the absence of stimulatory ligands (26). To confirm the
reported properties of the CCR5-T82P and CCR5-T82K CAMs,
we measured the proportion of ERK that was phosphorylated (P-
ERK) as a surrogate for CCR5 activation (41, 42). The propor-
tional phosphorylation of ERK was minimal, i.e., 8%, at baseline
(i.e., in the absence of any stimulation) in cells expressing CCR5-
WT, but it increased to 55% upon RANTES addition (Fig. 4).
Conversely, ERK phosphorylation in cells expressing either
CCR5-T82P or CCR5-T82K was high at baseline, at 56% or 58%,
respectively, and comparable to the RANTES-stimulated levels
seen in cells expressing CCR5-WT. RANTES treatment of CCR5-
T82P- or CCR5-T82K-expressing cells did not significantly affect
ERK phosphorylation. When the inverse agonist TAK779 was
added to the cells, ERK1/2 phosphorylation was not affected in
cells expressing CCR5-WT, but there were significant decreases in
P-ERK1/2 levels in cells expressing CCR5-T82P or CCR5-T82K,
from 56% to 21% and from 58% to 28%, respectively (Fig. 4).
Hence, the inverse agonist TAK779 does indeed reverse the con-
stitutive activity of the CCR5 CAMs.
We tested the above CCR5 mutants for the ability to mediate
HIV-1 entry in the presence or absence of VVC. To do so, U87-
CD4 cells were transfected with CCR5-WT, the CCR5-T82P or
CCR5-T82KCAM, or the CCR5-R126N SDM. The various CCR5
FIG 3 Effect of the PKA inhibitor H89 on inhibition of HIV-1 replication by VVC. (A) CD4 T cells were treated for 1 h with a range of H89 concentrations and
then either lysed to allowmeasurement of PKA activity or infected with the Res-4V3 virus for 6 h before washing. The data represent PKA activities expressed as
percentages of that in the absence of inhibitor (100%). The average values (	 SEM) for two independent experiments, using CD4T cells from a different donor
in each experiment, are shown by gray bars. The infectivity of the Res-4V3 virus was measured by p24 ELISA at 7 days postinfection (black line). Data for one
experiment using CD4 T cells pooled from the same two donors used to measure PKA activity are shown. (B and C) CD4 T cells were treated overnight with
or without PTX (100 ng/ml), incubated with H89 (10 M) and a range of VVC concentrations for 1 h, and then infected with the VVC-sensitive Par-4V3 virus
(B) or the VVC-resistant Res-4V3 virus (C), as indicated. The cells were washed 6 h later and then supplemented with medium containing the same VVC
concentrations. The data represent the percent inhibition of HIV-1 replication (measured at 7 days postinfection by p24 ELISA) relative to that in the absence of
VVC (0%). The average values (	 SEM) for three independent experiments, using CD4 T cells from a different donor in each experiment, are shown in panels
B and C.
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proteins were all expressed on the cell surface at similar levels, as
detected by MAb 2D7 or PA14 (data not shown). The CCR5-
transfected cells were then infected with viruses pseudotyped with
the VVC-sensitive or -resistant Env protein derived from Par-
4V3, Res-4V3, or Res-3FP. As Par-3FP generally behaves similarly
to Par-4V3, we did not include it in this experiment.
VVC inhibited the entry of Par-4V3 much more potently
(10-fold decrease in EC50; P  0.050) via the CCR5-R126N
SDM than via CCR5-WT. Moreover, the MPIs were higher when
the two resistant viruses entered via the SDM than when they
entered via CCR5-WT; for Res-4V3 and Res-3FP, there were 1.5-
fold and 2.7-fold (P  0.047 and P  0.050) decreases, respec-
tively, in the extent of residual (i.e., VVC-insensitive) infection
(Fig. 5). The VVC inhibition patterns for the two CCR5 CAMs
differed from each other and from that for the CCR5-R126N
SDM. VVC inhibited all three Env-pseudotyped viruses in cells
expressing the CCR5-T82P CAM, although to different extents.
Par-4V3 entry via CCR5-T82P was inhibited slightly more po-
tently (2-fold decrease in EC50; P 0.10) than that via CCR5-WT,
but for both resistant viruses, the MPI values were lower when
entry was via CCR5-T82P than when it was via CCR5-WT. Thus,
VVC-insensitive residual entry via CCR5-T82P was increased
2-fold and 1.5-fold (P  0.032 and P  0.048) for Res-4V3 and
Res-3FP, respectively (Fig. 6). The baseline (i.e., no VVC) entry
levels of Par-4V3, Res-4V3, and Res-3FP via the CCR5-T82K
FIG 4 ERK phosphorylation in cells expressing CCR5-WT or CCR5 CAMs. (A)
U87-CD4cellswere transfectedwithCCR5-WT,CCR5-T82P, orCCR5-T82K for
48handthen incubatedwithorwithoutRANTESfor5minorwithTAK779 for15
min. The cells were lysed and their proteins analyzed by SDS-PAGE. Antibodies
were used to probe for P-ERK and ERK. Both antibodies detect the p44 and p42
subunits of ERK1/2, as indicated. (B) The band intensities in panel A were quan-
tified, and the extents of ERK phosphorylation (P-ERK1/2) relative to total ERK
(ERK1/2) are expressed as percentages. Data shown are for one representative
experiment out of two with similar patterns of results.
FIG 5 HIV-1 entry via the CCR5-R126N SDM. U87-CD4 cells were transfected with CCR5-WT or the CCR5-R126Nmutant for 48 h and then incubated with
a range of VVC concentrations for 1 h prior to infection with the Env-pseudotyped virus Par-4V3 (A), Res-4V3 (B), or Res-3FP (C), as indicated. The data
represent the percent inhibition of HIV-1 entry (measured at 3 days postinfection by using a luciferase assay) relative to that in the absence of VVC (0%). The
average values (	 SEM) for three independent experiments are shown in all panels.
Berro et al.
6574 jvi.asm.org Journal of Virology
CAM were reduced by approximately 50%, 90%, and 50%, re-
spectively, compared to that via CCR5-WT (Fig. 6D). Thus, al-
though theCCR5-T82KCAM is a coreceptor forHIV-1 entry, this
function is impaired to various extents. Note that baseline entry of
all viruses via the CCR5-T82P CAM or the CCR5-R126N SDM
was generally comparable to entry via CCR5-WT (data not
shown). In contrast to what was seen with the other CAM, CCR5-
T82P, VVC inhibited none of the test viruses in cells expressing
CCR5-T82K (Fig. 6). One explanation for this finding is that the
T82K substitution destroys the VVC-binding site. However,
Res-4V3 (and, to a lesser extent, Res-3FP) entry via CCR5-T82K
was enhanced by VVC concentrations above 100 nM (Fig. 6B
and C). Thus, when VVC was added at 1 M, Res-4V3 entry was
significantly increased (3-fold; P  0.029), and Res-3FP entry
marginally so (1.7-fold; P 0.034), compared to when VVC was
absent (Fig. 6D). VVCmust therefore still bind to CCR5-T82K, at
least at concentrations above 100 nM. The resulting VVC–
CCR5-T82K complex is a more effective coreceptor for Res-4V3
and Res-3FP than the corresponding VVC-free form. Under the
same conditions, entry of the Par-4V3 parental virus was not de-
tectably affected by VVC (Fig. 6D). Par-4V3may therefore be able
to enter cells via the VVC complex of CCR5-T82K about as effi-
ciently as it can via free CCR5-T82K (see the model in Fig. 8);
alternatively, VVCmaybind toCCR5-T82Kwith an affinity that is
too low to prevent Env from interacting with this receptor. Note
that similar results were obtained with CCR5-T82K when MVC
was used instead of VVC (data not shown). The entry-enhancing
effect of VVC via CCR5-T82K was not attributable to a VVC-
mediated increase in the cell surface expression of this mutant, as
judged by staining with MAb PA14 or 2D7 (data not shown).
These antibodies were chosen because their binding to CCR5 is
not affected byVVCor other related inhibitors (6, 24, 43).Overall,
the T82K substitutionmust not just activate constitutive signaling
but also change the conformation of CCR5 in various ways that
affect both the VVC- and Env-binding sites.
In summary, the overall data pattern derived using the SDM is
FIG 6 HIV-1 entry via the CCR5 CAMs. (A to C) The experimental conditions were as described in the legend to Fig. 5, except that the CCR5-T82P and CCR5-T82K
mutantswerecomparedwithCCR5-WT. (D)Entryof the indicatedvirusesviaCCR5-T82Kin thepresence (blackbars)orabsence (graybars)ofVVC(1M),expressed
as percentages of the entry via CCR5-WT. The average values (	 SEM) for four independent experiments are shown in all panels, and P values (
0.05) for differences
in entry in the presence and absence of VVC are displayed in panel D. The data set in panel D is independent from those displayed in panels A to C.
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generally consistent with the results obtained using PTX. Thus, un-
coupling CCR5 from the intracellular signaling machinery, either
throughPTXorbymutating theDRYmotif, increased thepotencyof
VVC against the parental virus but decreased the efficiency with
which the resistant viruses used the VVC-CCR5 complex. Con-
versely, the resistant viruses Res-4V3 and, to a lesser extent, Res-3FP
use the VVC-bound form of the CCR5-T82P CAMmore efficiently
than the corresponding form of CCR5-WT, as indicated by the de-
creased MPI values (and hence the increased residual entry). The
T82K substitution appears to havemultiple effects, including an im-
pairment of HIV-1 entry, but the complex between VVC (at high
concentrations) and theCCR5-T82Kmutant canbeused for entryby
VVC-resistant, and possibly also VVC-sensitive, viruses under ap-
propriate circumstances. The latter point is explored further in the
section on CCR5modeling (see below).
AffinityofVVCforG-protein-coupledanduncoupled recep-
tors. To further understand the different VVC inhibition patterns
obtained for cells expressing the various CCR5 variants, we tested
whether the activation state of CCR5 affects its affinity for VVC.
To do so, we measured the ability of increasing VVC concentra-
tions to compete with a saturating amount of 125I-RANTES (i.e.,
CCL5) for binding to CCR5-WT, the CCR5-T82P and CCR5-
T82K CAMs, and the CCR5-R126N SDM, all expressed in U87-
CD4 cells. Nontransfected U87-CD4 cells were used to gauge and
correct for nonspecific 125I-RANTES binding. In the absence of
VVC, the 125I-RANTES probe bound to CCR5-WT, CCR5-T82P,
and CCR5-R126N to similar extents, but its binding to CCR5-
T82K was significantly reduced, by 60%, relative to that to
CCR5-WT (Fig. 7A). This outcome again speaks to the impact
that the T82K substitution must have on the conformation of the
ligand-binding regions of CCR5.
The competition curves showed that VVC inhibited 125I-
RANTES binding to all the CCR5 proteins except for CCR5-T82K
(Fig. 7B). The latter finding implies that RANTES can still bind to
the VVC–CCR5-T82K complex, an outcome consistent with the
ability of Par-4V3 to use the same complex for entry (Fig. 6A).
Hence, when sufficient VVC is present to form a low-affinity com-
plex with the CCR5-T82K mutant, the receptor may still be rec-
ognized by either HIV-1 or RANTES (see the model in Fig. 8).
Other possibilities are that the affinity of VVC for CCR5-T82K is
too low to block Env and RANTES binding or that RANTES and
VVC bind preferentially to different subpopulations of CCR5-
T82K. The EC50s for VVC inhibition of
125I-RANTES binding
were modestly lower for both CCR5-T82P and CCR5-R126N, by
2.8- and 2.4-fold (P 0.050 and P 0.028), respectively, than for
CCR5-WT (Fig. 7).
Overall, the VVC affinities of the various CCR5 variants did
not correlate with their differential usage by the VVC-resistant
viruses. Thus, VVC bound to both the CCR5-T82P CAM and the
CCR5-R126N SDM with slightly higher affinities than to CCR5-
WT, but the corresponding MPIs for the resistant viruses were
modestly decreased and increased, respectively, again compared
to CCR5-WT. The EC50s for VVC inhibition of the VVC-sensitive
viruswere somewhat lower for entry viaCCR5-R126NandCCR5-
T82P than for that via CCR5-WT, an outcome that is consistent
with the modest increase in VVC affinity for the two mutants.
Structural modeling of the CCR5 variants. The three-dimen-
sional (3D) structures of the WT, T82K, and R126N CCR5 vari-
ants were generated using a method that predicts the ensemble of
low-energy conformational states a GPCR can adopt (44). The
GEnSeMBLE technique involves sampling all reasonable packings
of the 7-helix bundle (we examined 13 trillion different helix
bundle packings) and then selecting an ensemble of 100 low-en-
ergy packings that are likely to play a role in binding various li-
gands and in the GPCR activation process. The resulting set of
CCR5-WT conformations, ranked from lowest to highest energy,
is referred to as wt1 to wt100.
The wt1 conformation is the lowest-energy form (i.e., themost
stable) that CCR5-WT can adopt. We refer to this conformation
asWT-apo (Fig. 8A).We dockedMVC and VVC into the 10most
structurally diverse conformations from among the 20 with the
lowest energies (i.e., wt1 to wt20) and then ranked the resulting
docked structures according to their energies. The outcome was
that both MVC and VVC stabilized the same conformation, wt7,
which became the most stable. This conformation is designated
WT-bound (Fig. 8A). Comparing the WT-apo and WT-bound
structures reveals that upon inhibitor binding, TM2 tilts slightly
toward the center of theTMbundle, while TM3 tilts away from the
center; the net effect is to reduce the distance between the intra-
cellular ends of TM3 and TM6 (see overlay in Fig. 8A). We next
introduced the T82K and R126N substitutions into all 100 con-
formations (wt1 to wt100) to assess their effects on CCR5 struc-
ture. The resulting conformations were then reranked and the
most stable selected. Note that, for simplicity, we retained the
same, “wt”-based nomenclature for the two CCR5 variants. For
the CCR5-T82Kmutant, conformation wt6 became the most sta-
ble (shown in Fig. 8B as T82K-apo).When unbound CCR5-T82K
was compared to unboundCCR5-WT,most of the helical changes
were located in TM2, TM3, and TM4. When MVC or VVC was
FIG 7 Competition between VVC and 125I-RANTES for binding to CCR5
variants. U87-CD4 cells were transfected for 48 h with CCR5-WT or the mu-
tants listed and then incubated for 1 h with 400 pM 25I-RANTES in the pres-
ence or absence of the indicated VVC concentrations. After extensive washing,
the amount of cell-bound 125I-RANTES was measured using a gamma scintil-
lation counter. (A) 125I-RANTESbinding to the indicatedCCR5 variants in the
absence of VVC was expressed as a percentage of binding to CCR5-WT. (B)
The data represent the percent inhibition of 125I-RANTES binding to each
CCR5 variant relative to that in the absence of VVC (0%). The average val-
ues (	 SEM) for three independent experiments are shown in all panels.
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docked into the CCR5-T82K CAM, the wt31 conformation be-
came the lowest-energy form in both cases (shown in Fig. 8B as
T82K-bound). Note that both inhibitor-bound CCR5-T82K vari-
ants acquired conformations similar to that of unbound CCR5-
WT. In fact, except for TM1 and TM4, the positions of the T82K-
bound andWT-apo TMhelices seem to be identical. In particular,
TM3 and TM2 completely overlap for T82K-bound andWT-apo
but are oriented differently in T82-apo (see overlay in Fig. 8B).
The analogous modeling study on the CCR5-R126N SDM re-
vealed that this variant can adopt multiple conformations with
comparable low-energy states, which implies that it has a certain
degree of structural flexibility. The lowest-energy conformation
for CCR5-R126N is wt37 (shown in Fig. 8C as R126N-apo), al-
though a few other structurally similar conformations with simi-
larly low energies can also be adopted. As with T82K-apo, most of
the helical changes in R126N-apo are located in TM2, TM3, and
FIG8 TMbundle structure and orientation of the low-energy conformational state for CCR5 variants. (A) TheTMhelices of the unboundCCR5-WT (WT-apo)
and MVC/VVC-bound CCR5-WT (WT-bound) structures predicted to have the lowest-energy conformations by the GEnSeMBLE method are superimposed.
Either MVC (cyan) or VVC (orange) is docked into the TM bundle. (B and C) The TM helices of unbound CCR5-WT (WT-apo) and the unbound and
VVC-bound forms of the indicated CCR5 variant are superimposed. (D) Three VVC orientations upon docking into the TM bundles are displayed in different
colors, i.e., red, green, and blue, for VVC-bound CCR5-WT (WT-bound), CCR5-T82K (T82K-bound), and CCR5-R126N (R126N-bound), respectively. The
extracellular loops (ECLs) of theWT-bound VVC are shown, and the space where VVC could potentially interact with ECL2 is depicted with a dotted circle. The
location of Thr (T) or Lys (K) at position 82 is indicated. In all panels, the TM region at the extracellular end is facing forward.
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TM4. The binding of VVC orMVC stabilized the wt41 conforma-
tion of CCR5-R126N (shown in Fig. 8C as R126N-bound). As
seen with CCR5-T82K, the inhibitor-bound form of CCR5-
R126N adopted a conformation similar to that of unbound
CCR5-WT.
The docking studies predict that MVC and VVC share a bind-
ing site on CCR5-WT and bind in similar orientations. The bind-
ing ofMVCwithin the TMbundle involves interactions withW86
(TM2), Y108 (TM3), Y251 (TM6), and E283 (TM7). VVC also
interacts with W86 (TM2), Y251 (TM6), and E283 (TM7), but
unlike MVC, it is not predicted to interact directly with Y108
(TM3) (Fig. 8A). The different outcomes for Y108 may reflect a
weakness in the side chain placement method (SCREAM) used to
predict how ligands are orientated within the TM bundle. In fact,
the position of the C- atom of Y108 suggests that it is indeed
located close enough to VVC for an interaction to be possible. In
previous mutagenesis-based studies, the residues identified as in-
teracting with VVC and MVC were similar to those predicted by
our models, although there were subtle differences in the extent
andnature of the interactions of the two inhibitorswith individual
residues (45–47). Overall, MVC and VVC are predicted to have a
commonbinding sitewithin the TMbundle and to contact similar
residues, albeit with perhaps some differences in their modes of
binding. The modeling study predicts that VVC acquires a differ-
ent orientation within each of the three CCR5 variants (Fig. 8D).
The VVC-bound conformations of CCR5-R126N and CCR5-
T82K are very similar, although the orientations of VVC differ
slightly between the two variants. The introduction of a positively
charged bulky residue when Thr-82 is replaced by Lys changes
how the drug is oriented, specifically by slightly shifting its posi-
tion toward TM4 compared to where it is located in CCR5-WT.
For CCR5-R126N, the VVC location shifts again, but closer to
TM5 and upward toward ECL2; the smaller upward shift enables
VVC to interact with themiddle section of the ECL2 loop, which is
not the case with the other two CCR5 variants. The location of
VVC in CCR5-R126N is most likely affected by the overall con-
formational change that the Arg-to-Asn substitution confers on
the CCR5 structure rather than by any more direct impact on the
inhibitor-binding site. That supposition is consistent with the lo-
cation of the R126N substitution in the DRYmotif at the intracel-
lular interface of TM3, a considerable distance from where VVC
binds.
The predicted structures of the VVC complexes with CCR5-
WT, CCR5-T82K, and CCR5-R126N indicate that the drug binds
to CCR5-T82K and CCR5-R126N more weakly and more
strongly, respectively, than to CCR5-WT, as approximated by the
binding enthalpy (H). Note that the relative affinity estimates for
VVC for CCR5-R126N and CCR5-WT, derived from the 125I-
RANTES competition assay (Fig. 7), are consistent with the pre-
dictions for MVC, with CCR5-R126N having the higher affinity.
Overall, 3D modeling of the CCR5 structure shows that VVC
still binds to CCR5-T82K, but in doing so it changes the mutant’s
conformation to one that is similar to unbound CCR5-WT. This
outcome explainswhyPar-4V3 could still use the inhibitor-bound
form of CCR5-T82K for entry and why the VVC-resistant viruses
used this complex more efficiently than unbound CCR5-T82K.
Although the inhibitor-bound form of CCR5-R126N also has a
conformation similar to that of unbound CCR5-WT, the VVC-
sensitive viruses did not use this complex, and the VVC-resistant
viruses did so only inefficiently. The modeling study suggests that
when VVC is bound to CCR5-R126N, the inhibitor is oriented in
a way that allows it to interact with ECL2, which is an important
element of the Env-binding site. A plausible outcome is a change
in the conformation of ECL2 that is sufficient to impede HIV-1
entry either substantially or completely, depending on the test
virus.
DISCUSSION
In this study, we assessed how CCR5 conformational/functional
variants influence the sensitivity of HIV-1 to small-molecule
CCR5 inhibitors, exemplified by VVC. In particular, we investi-
gated whether VVC’s action against inhibitor-sensitive and -resis-
tant viruses is affected by the state of CCR5 coupling toGproteins.
One finding is that uncoupling CCR5 from theGi subunit, either
by treating cells with PTX or by expressing the CCR5-R126N
SDM, increased the potency of VVC against a VVC-sensitive virus
but decreased the efficiency with which resistant viruses entered
cells via the VVC-CCR5 complex. Our results also indicate that
the observed effects of Gi subunit uncoupling on sensitivity to
VVC are unlikely to bemediated by downstream signaling events,
such as PKA activation, but rather by conformational changes in
CCR5. When we assessed the VVC sensitivity of viruses entering
cells via two constitutively active CCR5 variants, we observed that
VVC-resistant viruses used the inhibitor-bound form of the
CCR5-T82P CAM more efficiently than the corresponding VVC
complex of CCR5-WT. Entry via the CCR5-T82K CAM was im-
paired compared to that via CCR5-WT, but the resistant viruses
used this variant more efficiently when a VVC concentration high
enough to allow formation of the inhibitor-CCR5 complex was
present.
Differences in the affinities of the CCR5 variants for VVC do
not explain the variations in how efficiently the VVC-resistant
viruses used the various inhibitor-CCR5 complexes. Thus, based
on its ability to inhibit 125I-RANTES binding, we infer that VVC
has slightly higher affinities for both the CCR5-T82P CAM and
the CCR5-R126N SDM than for CCR5-WT. However, the resis-
tant viruses entered via the VVC-bound forms of these two vari-
ants with higher and lower efficiencies, respectively, than that for
the VVC complex with CCR5-WT.Having said that, the EC50s for
VVC against the sensitive virus were modestly lower when entry
was via CCR5-R126N and CCR5-T82P than when it was via
CCR5-WT. For these three CCR5 variants, the EC50s for the sen-
sitive virus, but not the MPI values for the resistant viruses, rank
similarly to the corresponding VVC affinities (i.e., to the EC50s for
VVC inhibition of 125I-RANTES binding).
The T82K substitution adversely affected HIV-1 entry, but in-
fection by the VVC-resistant viruses via the CCR5-T82K CAM
was enhanced by high VVC concentrations. Hence, VVC and
CCR5-T82K must form a complex that the resistant viruses use
more efficiently than the corresponding inhibitor-free configura-
tion. Conversely, VVC did not prevent inhibitor-sensitive viruses
from entering via CCR5-T82K; the extents of entry were similar
whether high VVC concentrations were present or not. The mod-
eling data suggest that when the CCR5-T82K variant binds VVC,
it acquires a conformation similar to that of unbound CCR5-WT.
The VVC-sensitive virus can use that CCR5 conformation(s) for
entry with the same efficiency as it can enter via unbound CCR5-
T82K, while the VVC-resistant viruses actually use it more effi-
ciently than the inhibitor-free form, leading to enhanced entry.
Although the predicted TM bundle structures are similar for un-
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bound CCR5-WT and inhibitor-bound CCR5-T82K, the loop
orientations for these receptors might differ, particularly when
VVC is bound. Such an effect might explain the observed sub-
maximal entry for Par-4V3 via CCR5-T82K in the presence of
VVC relative to that via CCR5-WT. The virology and modeling
studies strongly suggest that VVC andMVC behave very similarly
in how they interact with CCR5-WT and its variants. Althoughwe
cannot exclude the possibility of subtle, molecule-specific differ-
ences, none was evident when MVC or VVC was docked into
CCR5, as both compounds stabilized the same TM bundle con-
formations of all three CCR5 variants. However, there must be
inhibitor-specific conformational changes in themore flexible ex-
tracellular loop structures, given the variation in binding of ECL-
specific MAbs to CCR5 complexes with different small-molecule
inhibitors (43). Having said that, the MAb-binding profiles of
MVC-CCR5 and VVC-CCR5 complexes were very similar to one
another, although bothwere different fromCCR5 complexes with
other small-molecule inhibitors, such as aplaviroc (APL) (45).
These inhibitor-specific conformational changes in the ECLs are,
however, still sufficient to influence the cross-resistance profiles of
MVC- versus VVC-selected viruses (8–10, 43).
The effect the T82K substitution has on VVC sensitivity does
not imply that residue 82 is necessarily part of the inhibitor-bind-
ing site, just as it is unlikely to be involved directly in HIV-1 bind-
ing. Instead, our modeling shows that introducing a positively
charged lysine at this position within TM2 causes a substantial
structural rearrangement within the body of CCR5. Note that an
Ile-Met change at position 189 in TM5 indirectly compromises
the antiviral activity of a different CCR5 inhibitor, SCH-C, again
without this residue being part of the inhibitor-binding site (48).
Another probable long-range effect on the CCR5 structure in-
volves the T82A substitution, which partially impairs the inhibi-
tory activity of TAK779 but not that of other small molecules,
including AD101 and SCH-C (7, 27). Overall, the two changes at
residue 82 that create the CCR5-T82K and CCR5-T82P CAMs
have different effects onVVC andMVCbinding andHIV-1 entry,
presumably because they alter the overall geometry of CCR5 in
different ways that are not yet understood at the molecular level.
The conserved TXPmotif is present in TM2of all GPCRs of the
angiotensin, opioid, and chemokine families (49, 50). This se-
quence, residues 82 to 84, plays a crucial role in chemokine signal-
ing via CCR5. Depending on the type of substitution made at
residue Thr-82, the effect can range from strong impairment of
CCR5 activation by chemokines to constitutive activation in their
absence (26, 49, 50). Using ERK phosphorylation as a surrogate
for CCR5 activation, our results suggest that the CCR5-T82P and
CCR5-T82K variants have higher constitutive activity than that of
CCR5-WT. Earlier work has also shown that both theCCR5-T82P
and CCR5-T82K CAMs bind higher basal levels of GTPS than
that with CCR5-WT (i.e., they are constitutively coupled to G
proteins), but also that their overall properties are different (26).
Thus, CCR5-T82P can reach an active (i.e., G protein coupled)
state in the absence of chemokines but undergoes agonist-medi-
ated activation in calcium flux and chemotaxis assays. In contrast,
CCR5-T82K is more strongly activated constitutively but has a
dramatically impaired responsiveness to natural agonists that is
associated with reduced binding affinities (26). The data from our
chemokine binding assay are consistent with this earlier report:
125I-RANTES binding to CCR5-T82K, but not CCR5-T82P, was
severely compromised. Overall, the replacement of Thr-82 with
Pro or Lys creates two constitutively active CCR5 variants that
have distinct conformational and functional properties and are
recognized differently by HIV-1 and small-molecule inhibitors.
This point was further confirmed in a recent study in which both
CCR5-T82K and CCR5-T82P were reported to be constitutively
active but to differ in their ability tomediate HIV-1 Env-mediated
fusion (51).
Our results indicate that VVC-resistant viruses use the VVC-
bound formofG-protein-coupledCCR5more efficiently than the
corresponding form of the uncoupled receptor. Thus, how VVC
and similar antagonists inhibit these viruses depends largely on
their ability to stabilize G-protein-coupled or -uncoupled forms
of CCR5. In a recent study, MVC and TAK779 were shown to
stabilize slightly different CCR5 conformations that vary in the
ability to activate G proteins.More specifically, TAK779 preferen-
tially stabilized G-protein-uncoupled, inactive conformations,
while MVC bound equally well to both G-protein-coupled and
-uncoupled receptors. As a result, TAK779 was more effective
than MVC at stabilizing the G-protein-uncoupled, inactive state
of CCR5 (25). Whether our resistant viruses would use TAK779-
stabilized, G-protein-uncoupled receptors less efficiently than
their MVC-bound active and inactive counterparts remains to be
determined. The small-molecule inhibitor APL also stabilizes two
distinct CCR5 conformations with properties that differ depend-
ing on their coupling state: APL enhances RANTES binding to
uncoupled CCR5 but inhibits binding to the coupled form of the
receptor (52). Overall, the various small-molecule inhibitors may
stabilize different conformational subsets of CCR5 that also func-
tion differentially as coreceptors for resistant viruses.
An important unresolved issue is whether the abundances of
the different forms of CCR5 (coupled or uncoupled) are cell type
dependent or, alternatively, influenced by the activation state of a
cell. The amounts of CCR5 expressed in some transfected cell lines
may be greater than the levels of G proteins available for coupling,
creating an excess of uncoupled forms of CCR5. Thatmight not be
the case in primary cells. The different context for CCR5 might
explain why MPI values for resistant viruses are generally higher
for transiently or stably transfected cell lines than for primary cells,
as observed in our current and previous studies (24, 29). It is
conceivable that the CCR5 conformation status could also have
implications for the rates at which various stages of the fusion
process take place in different cells, and hence for the potencies of
inhibitors of different events in this process. Inhibitors affected in
this way could include neutralizing antibodies (NAbs) that inter-
vene against different stages of the virus-CD4-CCR5 binding axis,
leading to cell-type-dependent skews in how different NAb spec-
ificities are quantified.
Resting and activated T cells may also have different propor-
tions of CCR5 conformational/functional variants because of
changes in the relative amounts of CCR5 andGproteins expressed
under the two conditions. The formation of lipid rafts and the
recruitment of signalingmachinery to them are known to bemore
pronounced in activated cells, increasing the proportion of signal-
ing-active CCR5 forms present compared to the case in resting
cells (53, 54). Depending on the tissue compartment where infec-
tion occurs, the inhibitory actions of CCR5 inhibitors may be
influenced by the abundances of resting and active T cells, and
hence by the availability of G-protein-coupled and -uncoupled
forms of CCR5. It has been argued that resting T cells may be
involved in initial HIV-1 infections at mucosal sites, while infec-
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tion of activated T cells plays a far greater role during systemic
dissemination and propagation of the virus (55). In a recent study,
a substantial proportion of chronic viruses (but not transmitted/
founder viruses) were incompletely inhibited by a saturating con-
centration ofMVC (56, 57). This viral phenotype wasmost clearly
seen in a cell line expressing very high levels of both CD4 and
CCR5, but it was also detectable using primary CD4 T cells (56).
Our hypothesis is that CCR5 inhibitors might be particularly ef-
fective against HIV-1 mucosal transmission. Thus, the frequency
of incoming (i.e., transmitted/founder) viruses with reduced in-
hibitor susceptibility is lower than that seen with chronic viruses,
and infections of resting T cells, which may express a large pro-
portion of inhibitor-sensitive,G-protein-uncoupledCCR5 forms,
predominate at such sites. Note that CCR5 inhibitors can indeed
inhibit the vaginal transmission of test viruses to macaques when
applied topically or orally (58–61).
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